Trivascular Technologies (NASDAQ: TRIV) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it compare to its rivals? We will compare Trivascular Technologies to similar companies based on the strength of its analyst recommendations, profitability, risk, earnings, valuation, dividends and institutional ownership.
Valuation and Earnings
This table compares Trivascular Technologies and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Trivascular Technologies Competitors||$1.67 billion||$207.76 million||87.22|
This table compares Trivascular Technologies and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Trivascular Technologies Competitors||-100.14%||-92.44%||-29.75%|
This is a breakdown of current ratings and recommmendations for Trivascular Technologies and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Trivascular Technologies Competitors||128||739||1041||10||2.49|
As a group, “Medical Devices & Implants” companies have a potential upside of 42.69%. Given Trivascular Technologies’ rivals higher possible upside, analysts clearly believe Trivascular Technologies has less favorable growth aspects than its rivals.
Insider and Institutional Ownership
54.4% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 10.3% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Trivascular Technologies rivals beat Trivascular Technologies on 8 of the 8 factors compared.
Trivascular Technologies Company Profile
Trivascular Technologies, Inc. is a medical device company developing and commercializing technologies to advance minimally invasive treatment of abdominal aortic aneurysms (AAA). The Ovation System, the Company’s solution for the treatment of AAA through minimally invasive endovascular aortic repair, or EVAR, is a stent graft platform, providing an alternative to conventional devices. It is designed to specifically address many of the limitations associated with conventional EVAR devices and expand the pool of patients eligible for EVAR. The Company is developing Ovation iX iliac limbs for use with both its Ovation Prime and its Ovation iX and Alto aortic bodies, which are in development. Trivascular is developing Ovation iX aortic bodies for use with both its Ovation Prime and its Ovation iX iliac limbs. The Company is developing an aortic body that together with the iliac limbs makes up the Ovation Alto stent graft.
Receive News & Ratings for Trivascular Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trivascular Technologies and related companies with MarketBeat.com's FREE daily email newsletter.